多巴丝肼片联合神经节苷脂治疗帕金森病的临床效果及对认知功能、UPDRS评分的影响

Clinical Effect of Levodopa and Benserazide Combined with Ganglioside in the Treatment of Parkinson's Disease and Its Influence on Cognitive Function and UPDRS Score

目的对帕金森病采取多巴丝肼片联合神经节苷脂进行治疗的临床疗效和对患者认知功能以及UPDRS评分所产生的影响情况进行探讨。方法随机选择2019年1月—2021年1月接诊的帕金森病患者70例作为研究对象,按照随机数表法对其进行分组,对照组(n=35)患者接受多巴丝肼片进行治疗,研究组(n=35)患者接受多巴丝肼片联合神经节苷脂进行治疗,对比两组患者的临床疗效、实验室指标、认知功能以及UPDRS评分。结果两组帕金森病患者接受为期2周的治疗之后,研究组患者的总有效率(88.57%)明显高于对照组(68.57%),差异有统计学意义(χ^(2)=4.158,P=0.041);研究组患者的CD4^(+)和CD8^(+)以及中枢神经特异蛋白S100β明显优于对照组,差异有统计学意义(t=4.118,P<0.001;t=2.987,P=0.002;t=3.850,P<0.001);研究组患者的认知功能评分(87.25±4.78)分明显高于对照组(74.57±3.32)分,差异有统计学意义(t=12.890,P<0.001);研究组患者的UPDRS评分(37.21±9.84)分明显低于对照组(43.54±10.26)分,差异有统计学意义(t=2.634,P=0.005)。结论临床中对帕金森病患者采取多巴丝肼片联合神经节苷脂进行治疗的疗效确切,能够显著改善患者的认知功能与实验室指标,可推广使用。

Objective To explore the clinical efficacy of levodopa and benserazide combined with ganglioside in the treatment of Parkinson's disease and its influence on the cognitive function and UPDRS score of patients.Methods 70 patients with Parkinson's disease admitted to the hospital from January 2019 to January 2021 were randomly selected as the research objects,and they were grouped according to the random number table method.The control group(n=35)patients received levodopa and benserazide for treatment,and the study group(n=35)received levodopa and benserazide combined with ganglioside for treatment.The clinical efficacy,laboratory indicators,cognitive function and UPDRS scores were compared between the two groups.Results After two groups of Parkinson's disease patients received 2-week treatment,the total effective rate of the study group(88.57%)was significantly higher than that of the control group(68.57%),and the difference was statistically significant(χ^(2)=4.158,P=0.041).The CD4^(+) and CD8^(+) and central nervous system specific protein S100βof the patients in the study group were significantly better than those in the control group,and the difference was statistically significant(t=4.118,P<0.001;t=2.987,P=0.002;t=3.850,P<0.001).The cognitive function score of the patients in the study group(87.25±4.78)points was significantly higher than that of the control group(74.57±3.32)points,and the difference was statistically significant(t=12.890,P<0.001);the UPDRS score of the patients in the study group(37.21±9.84)points were significantly lower than the control group(43.54±10.26)points,and the difference was statistically significant(t=2.634,P=0.005).Conclusion The clinical efficacy of levodopa and benserazide combined with ganglioside in the treatment of Parkinson's disease patients is definite,and it can significantly improve the cognitive function and laboratory indicators of patients,and can be widely used.